San Francisco, United States
Osteoboost Health, established in 2018, is a pioneering company in the Health Care and Medical Devices industry, headquartered in the United States. The company is making significant strides with its product line focused on bone health. Its flagship product proudly holds the distinction of being the first and only FDA-approved non-pharmacological prescription treatment for low bone density, setting it apart from competitors.
In the rapidly evolving field of bone health technology, Osteoboost is providing millions with essential, safe alternatives or additions to existing therapies. The company recently secured a $5.00M investment in a Venture Round on March 4, 2024. This round saw participation from reputable investors such as Berkeley Catalyst Fund, Esplanade Ventures, and Terumo Cardiovascular Systems, signaling confidence in Osteoboost’s innovative approach and growth potential.
